EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2a, Genome Duplicate A

Ensembl ID : ENSGMOG00000005328
Gene Symbol: HTR2AA
2 Cross references
219 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSGMOG00000032489
Gene Symbol: HTR2CL1
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSGMOG00000017509
Gene Symbol: HTR5AB
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSGMOG00000007722
Gene Symbol: HTR1A
3 Cross references
135 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSGMOG00000020373
Gene Symbol: HTR1B
1 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSGMOG00000032964
Gene Symbol: HTR1E
3 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSGMOG00000024159
Gene Symbol: HTR3A
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSGMOG00000012790
Gene Symbol: HTR3A
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSGMOG00000034137
Gene Symbol: HTR4
2 Cross references
198 Possible Orthologues:

60s Ribosomal Protein L31

Ensembl ID : ENSGMOG00000034282
Gene Symbol: LOC115539041
2 Cross references
649 Possible Orthologues:

60s Ribosomal Protein L31

Ensembl ID : ENSGMOG00000031333
Gene Symbol: LOC115539041
2 Cross references
649 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSGMOG00000012642
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).